Targeting both pathways, via miR-325-3p upregulation or CXCL17/TAM inhibition, could offer novel therapeutic strategies to disrupt HCC neovascularization and impede tumor growth. The gene discussed is CXCL17; the disease is hepatocellular carcinoma.